Login to Your Account



Clinic Roundup


Monday, February 13, 2012
• Synageva BioPharma Corp., of Lexington, Mass., reported results from a four-week Phase I/II study of enzyme replacement candidate SBC-102 in adults with late onset lysosomal acid lipase (LAL) deficiency, showing the drug was well tolerated, with no serious adverse events or infusion-related reactions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription